Fritz Frederick J.
Known title: DirectorCIK: 0001525250
Fritz Frederick J.'s purchase track record
How the stock did after each of Fritz Frederick J.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since October 7, 2021
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-59.2%
3 months: -45.4%
Beat the S&P 500
0%
median -45.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/8/2022 | IMNN | $20K | -45.4% | -59.2% | -18.9% |
| 3/2/2022 | IMNN | $9K | -49.7% | -55.2% | -9.8% |
| 10/7/2021 | IMNN | $18K | -39.8% | -66.5% | +2.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMNN | ▲ Buy | Grant | 6,934 | $11K | 7/31/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 10,330 | $23K | 5/22/2026 | View on chart |
| IMNN | ▲ Buy | Grant | 3,161 | $29K | 8/4/2025 | View on chart |
| IMNN | ▲ Buy | Open Market | 5,000 | $20K | 4/8/2022 | View on chart |
| IMNN | ▲ Buy | Open Market | 2,000 | $9K | 3/2/2022 | View on chart |
| IMNN | ▲ Buy | Open Market | 20,000 | $18K | 10/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Imunon Shares Debt Conversion and Ovarian Cancer Data
Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.
Imunon Shares Debt Conversion and Ovarian Cancer Data. Imunon Inc. disclosed that it converted $1.2 million of debt into equity. Additionally, the company shared research data for IMNN-001 in frontline ovarian cancer during an R&D day. These updates provide context for the stock's current trading range, which remains well below the average analyst target price.